initial public offerings (IPOs) trading on American exchanges

Tuesday, October 15, 2013

Alcobra (ADHD)


Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.


4th Floor 35 Ehad Ha-Am Street

Website links

Key stats and ratios

Q2 (Jun '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets--224.77%
Return on average equity--755.50%

No comments:

Post a Comment